Amgen prepares to launch Eylea biosimilar amid ongoing legal battles

Amgen is set to launch its biosimilar version of Regeneron's Eylea, known as Pavblu, after receiving a favorable ruling from the U.S. Court of Appeals for the Federal Circuit.

Background

The court lifted a temporary injunction that had previously prevented Amgen from introducing the drug, rejecting Regeneron's claims that a market ban was necessary during the ongoing litigation.

This decision allows Amgen to enter a competitive market that has been dominated by Eylea, a drug that generated $1.53 billion in sales for Regeneron in the second quarter alone.

Regeneron's Response

Despite the court's ruling, Regeneron plans to continue defending its patent rights and expressed disappointment over the decision.

The company intends to pursue legal action against Amgen and is moving patients to a newer, high-dose version of Eylea.

Risks for Amgen

Amgen's decision to launch Pavblu at this time has surprised analysts, as it involves significant risk.

By entering the market now, Amgen could face substantial damages if the courts ultimately rule in favor of Regeneron regarding patent infringement.

Competitive Landscape

The competitive landscape for Eylea is becoming crowded, with multiple biosimilars receiving FDA approval.

This influx of competitors poses a threat to Regeneron's Eylea franchise and could lead to price competition.

Appeals Court Decision

The appeals court's decision to lift the injunction was based on factors such as the likelihood of success on appeal and the potential for irreparable harm to Regeneron.

Conclusion

As Amgen prepares to launch Pavblu, the company faces the challenge of navigating the legal landscape while competing in a rapidly evolving market.

The outcome of the ongoing litigation will be closely watched by investors and industry stakeholders, as it will set important precedents for future biosimilar launches and patent disputes in the industry.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings